19 July 2018 - - Boston, Massachusetts- and Hamilton, Ontario-based radiotherapeutics specialist Fusion Pharmaceuticals has appointed five internationally recognized clinician-scientists to its newly formed advisory board, the company said.
The members, academic and industry thought leaders with extensive experience advising a number of North American and European biotech companies, are Rosalyn Juergens, M.D., Ph.D., Deepak Khuntia, M.D., C. Gillies O'Bryan-Tear, M.D., MBA, Oliver Sartor, M.D., and Geoffrey Shapiro M.D., Ph.D.
They are all internationally renowned experts in oncology and radiation therapies, in particular Phase 1 oncology trials, radiopharmaceutical and antibody therapeutics, and advanced radiation treatments. The advisory board is composed of.
Juergens' clinical expertise is in lung and esophageal cancer. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre.
Khuntia is a board-certified radiation oncologist who serves as the SVP and CMO at Varian. In addition to his responsibilities at Varian, he continues to hold a part time clinical practice in Radiation Oncology in the Bay Area where he has a special interest in advanced radiation technologies, central nervous system tumors, head and neck cancer, and lung cancer.
O'Bryan-Tear is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and chair of the Policy and Communications Group, Faculty of Pharmaceutical Medicine and a Fellow at the Royal College of Physicians. He has spent 30 years in the pharmaceutical industry in clinical development, medical management and commercial roles.
Sartor is a medical oncologist with a special focus on prostate cancer. He is the Laborde Professor for Cancer Research, Medical director of the Tulane Cancer Center, and Assistant Dean for Oncology at Tulane University School of Medicine in New Orleans, LA.
Shapiro is Professor of Medicine at the Dana-Farber Cancer Institute, where he is director of the Early Drug Development Center, Clinical director of the Center for DNA Damage and Repair and co-Leader of the Dana-Farber/Harvard Cancer Center Program in Developmental Therapeutics.
He is a recognized leader in Phase 1 anti-cancer drug development, where he has focused on translational and clinical research of inhibitors of the cancer cell cycle, signal transduction and of DNA repair.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the targeted alpha therapy field. The company links medical isotopes to targeting molecules to create highly effective therapeutics.